PDCD1 and hepatocellular carcinoma: A comprehensive characterization of the molecular patterns associated with response and resistance in patients with advanced HCC treated with anti-PD1 has recently been reported, and therefore has the potential to maximize the efficiency of anti-PD1 application [178].